Executive dysfunction assessed by Clock-Drawing Test in older non-demented subjects with metabolic syndrome is not mediated by white matter lesions

Psychiatry and Clinical Neurosciences

Volumn 69, Issue 10, 2015, Pages 620-629

  Viscogliosi, Giovanni ^a,c   Chiriac, Iulia Maria ^b   Andreozzi, Paola ^a   Ettorre, Evaristo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Casa di Cura Merry House   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Clock Drawing Test; executive dysfunction; metabolic syndrome; prevention; white matter hyperintensities

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; BABCOCK SHORT STORY RECALL TEST; CLINICAL ARTICLE; CLOCK DRAWING TEST; COGNITION; COGNITIVE DEFECT; COGNITIVE FUNCTION TEST; COMMUNITY LIVING; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISODIC MEMORY; EXECUTIVE DYSFUNCTION; FAZEKAS SCALE; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; RATING SCALE; VERY ELDERLY; WHITE MATTER HYPERINTENSITY; WHITE MATTER LESION; COGNITION DISORDERS; COMPLICATION; EXECUTIVE FUNCTION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WHITE MATTER;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; NEUROPSYCHOLOGICAL TESTS; WHITE MATTER;

EID: 84943584386     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12296     Document Type: Article

References (34)

1. Fjell AM, Walhovd KB,. Structural brain changes in aging: Courses, causes and cognitive consequences. Rev. Neurosci. 2010; 21: 187-221.
2. Viscogliosi G, Marigliano V,. Alzheimer's disease: How far have we progressed? Lessons learned from diabetes mellitus, metabolic syndrome, and inflammation. J. Am. Geriatr. Soc. 2013; 61: 845-846.
3. Harrington MG, Chiang J, Pogoda JM, et al. Executive function changes before memory in preclinical Alzheimer's pathology: A prospective, cross-sectional, case-control study. PLoS ONE 2013; 8: e79378.
4. Viscogliosi G, Andreozzi P, Manzon L, Ettorre E, Cacciafesta M,. Metabolic syndrome, executive dysfunction, and late-onset depression: Just a matter of white matter? J. Am. Geriatr. Soc. 2014; 62: 1607-1608.
5. Hankee LD, Preis SR, Beiser AS, et al. Qualitative neuropsychological measures: Normative data on executive functioning tests from the Framingham offspring study. Exp. Aging Res. 2013; 39: 515-535.
6. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB,. Probability of stroke: A risk profile from the Framingham study. Stroke 1991; 22: 312-318.
7. Wang P, Shi L, Zhao Q, Hong Z, Guo Q,. Longitudinal changes in the clock drawing test (CDT) performance before and after cognitive decline. PLoS ONE 2014; 9: e97873.
8. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77: 461-468.
9. Tan ZS, Beiser AS, Fox CS, et al. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults. Diabetes Care 2011; 34: 1766-1770.
10. Scuteri A,. Brain injury as end-organ damage in hypertension. Lancet Neurol. 2012; 11: 1015-1017.
11. Portet F, Brickman AM, Stern Y, et al. Metabolic syndrome and localization of white matter hyperintensities in the elderly population. Alzheimers Dement. 2012; 8: S88-S95.
12. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H,. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008; 39: 1607-1609.
13. Raffaitin C, Gin H, Empana JP, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: The Three-City study. Diabetes Care 2009; 32: 169-174.
14. Komulainen P, Lakka TA, Kivipelto M, et al. Metabolic syndrome and cognitive function: A population-based follow-up study in elderly women. Dement. Geriatr. Cogn. Disord. 2007; 23: 29-34.
15. Dik MG, Jonker C, Comijs HC, et al. Contribution of metabolic syndrome components to cognition in older persons. Diabetes Care 2007; 30: 2655-2660.
16. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA,. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement. Geriatr. Cogn. Disord. 2007; 24: 185-192.
17. McEvoy LK, Laughlin GA, Barrett-Connor E, et al. Metabolic syndrome and 16-year cognitive decline in community-dwelling older adults. Ann. Epidemiol. 2012; 22: 310-317.
18. Schuur M, Henneman P, van Swieten JC, et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur. J. Epidemiol. 2010; 25: 561-568.
19. Rouch I, Trombert B, Kossowsky MP, et al. Metabolic syndrome is associated with poor memory and executive performance in elderly community residents: The PROOF study. Am. J. Geriatr. Psychiatry 2014; 22: 1096-1104.
20. Reijmer YD, van der Berg E, Dekker JM, et al. The metabolic syndrome, atherosclerosis and cognitive functioning in a non-demented population: The Hoorn Study. Atherosclerosis 2011; 219: 839-845.
21. Falkowski J, Atchison T, Debutte-Smith M, Weiner MF, O'Bryant S,. Executive functioning and the metabolic syndrome: A project FRONTIER study. Arch. Clin. Neuropsychol. 2014; 29: 47-53.
22. Bokura H, Nagai A, Oguro H, Kobayashi S, Yamaguchi S,. The association of metabolic syndrome with executive dysfunction independent of subclinical ischemic lesions in Japanese adults. Dement. Geriatr. Cogn. Disord. 2010; 30: 479-485.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edn. Text Revision. American Psychiatric Association, Washington, DC, 2000.
24. O'Bryant SE, Waring SC, Cullum CM, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes score: A Texas Alzheimer's research consortium study. Arch. Neurol. 2008; 65: 1091-1095.
25. National Cholesterol Education Program. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
26. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am. J. Roentgenol. 1987; 149: 351-356.
27. Folstein MF, Folstein S, McHugh PR,. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975; 12: 189-198.
28. Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer's disease: A novel measure of dementia severity. J. Am. Geriatr. Soc. 1989; 37: 725-729.
29. De Renzi E, Faglioni P, Ruggini C,. Prove di memoria verbale ed impiego clinico per la diagnosi di amnesia. Arch. Psicol. Neurol. Psichiatr. 1977; 3: 303-308.
30. Torres RM, Miralles R, Garcia-Caselles MP, et al. Observational scale and geriatric depression scale of Yesavage to identify depressive symptoms in older patients. Arch. Gerontol. Geriatr. Suppl. 2004; (9): 437-442.
31. Scuteri A, Najjar SS, Orrù M, et al. The central arterial burden of the metabolic syndrome is similar in men and women: The SardiNIA Study. Eur. Heart J. 2010; 31: 602-613.
32. Ferrucci L, Cecchi F, Guralnik JM, et al. Does the Clock Drawing Test predict cognitive decline in older persons independent of the Mini-Mental State Examination? J. Am. Geriatr. Soc. 1996; 44: 1326-1331.
33. Freund B, Gravenstein S, Ferris R, Burke BL, Shaheen E,. Drawing clocks and driving cars. J. Gen. Intern. Med. 2005; 20: 240-244.
34. Rubio-Perez JM, Morillas-Ruiz JM,. A review: Inflammatory process in Alzheimer's disease, role of cytokines. Mol. Neurobiol. 2010; 41: 392-409.